Article Sidebar

Download
PDF (Bahasa Indonesia)
Statistic
Read Counter : 31 Download : 27

Downloads

Download data is not yet available.

Main Article Content

Abstract

Proton pump inhibitor (PPI) is a drug with a good safety profile and effectiveness for patients with various conditions, so it is routinely prescribed around the world, one of them at PKU Muhammadiyah Gamping Yogyakarta. The aim of this study is to find out the profile of PPI drug use and the appropriate doses of the PPI group of drugs in hospitalized patients. This study is a descriptive observational study with a cross-sectional design. Data collection through secondary data is 200 patient medical records retrospectively. The results of the study showed the highest diagnosis of PPI drug use for gastro (60.50%) and non-gastro (39.50%). There are drugs that are given to patients at risk of gastrointestinal bleeding: NSAIDs (88.4%), glucocorticosteroids (8.97%), and anticoagulants (2.56%). The types of PPI used are pantoprazole injections 40 mg, lansoprazole tablets 30 mg, and lansoprazole injections 30 mg. The accurate dosage appropriate of PPI use is 100%.

Keywords

Proton Pump Inhibitor (PPI) drug profile drug evaluation dosage appropriate

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Author Biographies

Chynthia Pradiftha Sari, Jurusan Farmasi, Universitas Islam Indonesia, Yogyakarta

Jurusan Farmasi, Universitas Islam Indonesia, Yogyakarta

Chintia Khairunnisa Rachman, Jurusan Farmasi, Universitas Islam Indonesia, Yogyakarta

Jurusan Farmasi, Universitas Islam Indonesia, Yogyakarta

Suci Hanifah, Jurusan Farmasi, Universitas Islam Indonesia, Yogyakarta

Jurusan Farmasi, Universitas Islam Indonesia, Yogyakarta

Isti Mutmainah, Instalasi Farmasi Rumah Sakit, RS PKU Muhammadiyah Gamping, Yogyakarta

Instalasi Farmasi Rumah Sakit, RS PKU Muhammadiyah Gamping, Yogyakarta
How to Cite
Sari, C. P., Rachman, C. K., Hanifah, S., & Mutmainah, I. (2024). EVALUTION OF PROTON PUMP INHIBITOR DRUG IN INPATIENTS AT PKU MUHAMMADIYAH GAMPING HOSPITAL, YOGYAKARTA. Borneo Journal of Pharmascientech, 8(2), 207-213. https://doi.org/10.51817/bjp.v8i2.575
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Abbas, M. K., Zaidi, A. R. Z., Robert, C. A., Thiha, S., & Malik, B. H. (2019). The Safety of Long-term Daily Usage of a Proton Pump Inhibitor: A Literature Review. Cureus, 11(9), e5563. https://doi.org/10.7759/cureus.5563
  2. Abrignani, M. G., Lombardo, A., Braschi, A., Renda, N., & Abrignani, V. (2023). Proton pump inhibitors and gastroprotection in patients treated with antithrombotic drugs: A cardiologic point of view. World J Cardiol, 15(8), 375-394. https://doi.org/10.4330/wjc.v15.i8.375
  3. Brisebois, S., Merati, A., & Giliberto, J. P. (2018). Proton pump inhibitors: Review of reported risks and controversies. Laryngoscope Investig Otolaryngol, 3(6), 457-462. https://doi.org/10.1002/lio2.187
  4. Dabrowski, A., Štabuc, B., & Lazebnik, L. (2018). Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease - PAN-STAR. Prz Gastroenterol, 13(1), 6-15. https://doi.org/10.5114/pg.2018.74556
  5. Danziger, J., William, J. H., Scott, D. J., Lee, J., Lehman, L. W., Mark, R. G., Howell, M. D., Celi, L. A., & Mukamal, K. J. (2013). Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int, 83(4), 692-699. https://doi.org/10.1038/ki.2012.452
  6. Gwee, K. A., Goh, V., Lima, G., & Setia, S. (2018). Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: risks versus benefits. J Pain Res, 11, 361-374. https://doi.org/10.2147/jpr.S156938
  7. Ierardi, E., Losurdo, G., Fortezza, R. F., Principi, M., Barone, M., & Leo, A. D. (2019). Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness. World J Gastroenterol, 25(34), 5097-5104. https://doi.org/10.3748/wjg.v25.i34.5097
  8. Janarthanan, S., Ditah, I., Adler, D. G., & Ehrinpreis, M. N. (2012). Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol, 107(7), 1001-1010. https://doi.org/10.1038/ajg.2012.179
  9. Katz, P. O., Dunbar, K. B., Schnoll-Sussman, F. H., Greer, K. B., Yadlapati, R., & Spechler, S. J. (2022). ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol, 117(1), 27-56. https://doi.org/10.14309/ajg.0000000000001538
  10. McColl, K. E. (2009). Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol, 104 Suppl 2, S5-9. https://doi.org/10.1038/ajg.2009.45
  11. Narum, S., Westergren, T., & Klemp, M. (2014). Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open, 4(5), e004587. https://doi.org/10.1136/bmjopen-2013-004587
  12. Peng, C. C., Tu, Y. K., Lee, G. Y., Chang, R. H., Huang, Y., Bukhari, K., Tsai, Y. C., Fu, Y., Huang, H. K., & Munir, K. M. (2021). Effects of Proton Pump Inhibitors on Glycemic Control and Incident Diabetes: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab, 106(11), 3354-3366. https://doi.org/10.1210/clinem/dgab353
  13. Pietrzak, A. (2023). Principles for the use of non-steroidal anti-inflammatory drugs with proton pump inhibitors. Polish Journal of Surgery.
  14. Pinto-Sanchez, M. I., Yuan, Y., Hassan, A., Bercik, P., & Moayyedi, P. (2017). Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev, 11(11), Cd011194. https://doi.org/10.1002/14651858.CD011194.pub3
  15. Scheiman, J. M. (2013). The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther, 15 Suppl 3(Suppl 3), S5. https://doi.org/10.1186/ar4177
  16. Shah, N. H., LePendu, P., Bauer-Mehren, A., Ghebremariam, Y. T., Iyer, S. V., Marcus, J., Nead, K. T., Cooke, J. P., & Leeper, N. J. (2015). Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population. PLoS One, 10(6), e0124653. https://doi.org/10.1371/journal.pone.0124653
  17. Strand, D. S., Kim, D., & Peura, D. A. (2017). 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver, 11(1), 27-37. https://doi.org/10.5009/gnl15502
  18. Xie, Y., Bowe, B., Li, T., Xian, H., Balasubramanian, S., & Al-Aly, Z. (2016). Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD. J Am Soc Nephrol, 27(10), 3153-3163. https://doi.org/10.1681/asn.2015121377
  19. Zhan, X. B., Guo, X. R., Li, Z. S., Gong, Y. F., Gao, J., Liao, Z., Li, Z., Gao, S., & Liu, P. (2012). Inhibitory effects of intravenous lansoprazole 30 mg and pantoprazole 40 mg twice daily on intragastric acidity in healthy Chinese volunteers: a randomized, open-labeled, two-way crossover study. Med Sci Monit, 18(2), Cr125-130. https://doi.org/10.12659/msm.882468